Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]

  • Awaiting development
  • GID-TA11723
  • Expected publication date: TBC
To appraise the clinical and cost effectiveness of Trastuzumab deruxtecan + Pertuzumab within its marketing authorisation for treating breast cancer